Safety and Efficacy of Antigen-Specific Regulatory T-Cell Therapy for Patients With Refractory Crohn's Disease

Fiocchi, 1998, Inflammatory bowel disease: etiology and pathogenesis, Gastroenterology, 115, 182, 10.1016/S0016-5085(98)70381-6 Peyrin-Biroulet, 2008, Crohn's disease: beyond antagonists of tumour necrosis factor, Lancet, 372, 67, 10.1016/S0140-6736(08)60995-2 Velayos, 2007, Positioning biologic therapy for Crohn's disease and ulcerative colitis, Curr Gastroenterol Rep, 9, 521, 10.1007/s11894-007-0069-1 Burt, 2010, Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up, Blood, 116, 6123, 10.1182/blood-2010-06-292391 Cassinotti, 2008, Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease, Gut, 57, 211, 10.1136/gut.2007.128694 Panes, 2010, Stem cell treatment for Crohn's disease, Expert Rev Clin Immunol, 6, 597, 10.1586/eci.10.27 Burra, 2011, Therapeutic application of stem cells in gastroenterology: an up-date, World J Gastroenterol, 17, 3870, 10.3748/wjg.v17.i34.3870 Duijvestein, 2010, Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study, Gut, 59, 1662, 10.1136/gut.2010.215152 Onken J, Gallup D, Hanson J, et al. Successful outpatient treatment of refractory Crohn's disease using adult mesenchymal stem cells. Paper presented at: American College of Gastroenterology conference; 2006. Allan, 2008, CD4+ T-regulatory cells: toward therapy for human diseases, Immunol Rev, 223, 391, 10.1111/j.1600-065X.2008.00634.x Allez, 2004, Regulatory T cells: peace keepers in the gut, Inflamm Bowel Dis, 10, 666, 10.1097/00054725-200409000-00027 Brusko, 2008, Human regulatory T cells: role in autoimmune disease and therapeutic opportunities, Immunol Rev, 223, 371, 10.1111/j.1600-065X.2008.00637.x Groux, 1997, A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis, Nature, 389, 737, 10.1038/39614 Roncarolo, 2006, Interleukin-10-secreting type 1 regulatory T cells in rodents and humans, Immunol Rev, 212, 28, 10.1111/j.0105-2896.2006.00420.x Weiner, 2001, Induction and mechanism of action of transforming growth factor-b- secreting Th3 regulatory cells, Immunol Rev, 182, 207, 10.1034/j.1600-065X.2001.1820117.x Chaturvedi, 2011, Cutting edge: human regulatory T cells require IL-35 to mediate suppression and infectious tolerance, J Immunol, 186, 6661, 10.4049/jimmunol.1100315 Foussat, 2003, A comparative study between T regulatory type 1 and CD4+CD25+ T cells in the control of inflammation, J Immunol, 171, 5018, 10.4049/jimmunol.171.10.5018 Ahangarani, 2009, In vivo induction of type 1-like regulatory T cells using genetically modified B cells confers long-term IL-10-dependent antigen-specific unresponsiveness, J Immunol, 183, 8232, 10.4049/jimmunol.0901777 Brun, 2009, Clinical grade production of IL-10 producing regulatory Tr1 lymphocytes for cell therapy of chronic inflammatory diseases, Int Immunopharmacol, 9, 609, 10.1016/j.intimp.2009.01.032 Bollyky, 2011, ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors, Proc Natl Acad Sci U S A, 108, 7938, 10.1073/pnas.1017360108 Haringer, 2009, Identification and characterization of IL-10/IFN-gamma-producing effector-like T cells with regulatory function in human blood, J Exp Med, 206, 1009, 10.1084/jem.20082238 Guideline on the development of new medicinal products for the treatment of Crohn's Disease. European Medicines Agency report number CPMP/EWP/2284/99Rev1, 2008. Irvine, 1999, Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease, J Pediatr Gastroenterol Nutr, 28, S23, 10.1097/00005176-199904001-00003 Bacchetta R, Sartirana C, Lucarelli B, et al. Interleukin-10 anergized donor T cell infusion improves immune reconstitution without severe graft-versus-host-disease after haploidentical hematopoietic stem cell transplantation. Presented at: 51st Annual Meeting of the American Society of Hematology; December 6, 2009; New Orleans, LA. Abstract 45. Brunstein, 2011, Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics, Blood, 117, 1061, 10.1182/blood-2010-07-293795 Di Ianni, 2011, Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation, Blood, 117, 3921, 10.1182/blood-2010-10-311894 Edinger, 2009, Regulatory T cells for the prevention of graft-versus-host disease: professionals defeat amateurs, Eur J Immunol, 39, 2966, 10.1002/eji.200940030 Wang, 2011, Regulatory T cells: customizing for the clinic, Sci Transl Med, 3, 10.1126/scitranslmed.3001819 Himmel, 2012, Regulatory T cell therapy for inflammatory bowel disease: more questions than answers, Immunology, 136, 115, 10.1111/j.1365-2567.2012.03572.x Maul, 2005, Peripheral and intestinal regulatory CD4+CD25high T cells in inflammatory bowel disease, Gastroenterology, 128, 1868, 10.1053/j.gastro.2005.03.043 Holmen, 2006, Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity, Inflamm Bowel Disease, 12, 447, 10.1097/00054725-200606000-00003 Rubtsov, 2008, Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces, Immunity, 28, 546, 10.1016/j.immuni.2008.02.017 Murai, 2009, Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis, Nat Immunol, 10, 1178, 10.1038/ni.1791 Braat, 2006, A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease, Clin Gastroenterol Hepatol, 4, 754, 10.1016/j.cgh.2006.03.028 Schreiber, 2000, Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease, Gastroenterology, 119, 1461, 10.1053/gast.2000.20196 Magnani, 2011, Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells, Eur J Immunol, 41, 1652, 10.1002/eji.201041120 Satoguina, 2008, Tr1 and naturally occurring regulatory T cells induce IgG4 in B cells through GITR/GITR-L interaction, IL-10 and TGF-beta, Eur J Immunol, 38, 3101, 10.1002/eji.200838193 Mandapathil, 2010, Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells, J Biol Chem, 285, 27571, 10.1074/jbc.M110.127100 Grainge, 2010, Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study, Lancet, 375, 657, 10.1016/S0140-6736(09)61963-2 Grip, 2007, Increased subpopulations of CD16(+) and CD56(+) blood monocytes in patients with active Crohn's disease, Inflamm Bowel Dis, 13, 566, 10.1002/ibd.20025 De Serres, 2009, Immunosuppressive drugs and Tregs: a critical evaluation!, Clin J Am Soc Nephrol, 4, 1661, 10.2215/CJN.03180509 Putzki, 2010, Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells, Eur Neurol, 63, 311, 10.1159/000302687 Boschetti, 2011, Therapy with anti-TNFα antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases, Inflamm Bowel Dis, 17, 160, 10.1002/ibd.21308 Li, 2010, Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab, Inflamm Bowel Dis, 16, 1299, 10.1002/ibd.21229 van Deventer, 1997, Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease, Gastroenterology, 113, 383, 10.1053/gast.1997.v113.pm9247454